Rendle, Katharine A.
Ramogola-Masire, Doreen
Monare, Barati
Ogden, Shannon N.
Toneff, Hannah K.
Saia, Chelsea A.
Wainwright, Jocelyn V.
Friebel-Klingner, Tara M.
Bazzett-Matabele, Lisa
Bhatia, Rohini
Bonner, Natalie
Ralefala, Tlotlo B.
Vuylsteke, Peter
Luckett, Rebecca
Grover, Surbhi
Funding for this research was provided by:
Penn Center for AIDS Research (CFAR) , NIH-Funded Program (P30 AI 045008, P30 AI 045008, P30 AI 045008, P30 AI 045008, P30 AI 045008, P30 AI 045008)
National Institute on Drug Abuse (T32DA041898)
National Cancer Institute (K08CA230170-03S1)
Article History
Received: 10 February 2022
Accepted: 19 May 2022
First Online: 28 May 2022
Declarations
:
: Patients who were eligible were given an informational consent statement about the study and written informed consent to participate was obtained. All study activities were approved by the institutional review boards at University of Pennsylvania (approval number: 832278), Princess Marina Hospital (approval number: PMH 5/79(177-1-2020), and Ministry of Health and Wellness of the Republic of Botswana (approval number: HPDME 13/18/1) prior to study conduct. All methods were carried out in accordance with the relevant guidelines and regulations.
: Not applicable.
: The authors declare that they have no competing interests.